Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Investigation

• Publication date

  2008-09-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI33337PMID 18704194PMCID PMC2515380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mammalian target of rapamycin as a therapeutic target in oncology.

  2008cited by this paper
• Targeting phosphoinositide 3-kinase: moving towards therapy.

  2008cited by this paper
• Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer

  2007cited by this paper
• Nutrient sensing in the mTOR/S6K1 signalling pathway.

  2007cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• The two TORCs and Akt.

  2007cited by this paper
• Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

  2007cited by this paper
• Akt1 governs breast cancer progression in vivo

  2007cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006cited by this paper
• A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice

  2006cited by this paper
• TOR signaling in growth and metabolism.

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  2006cited by this paper
• Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement

  2005cited by this paper
• ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.

  2005cited by this paper
• Signalling by PI3K isoforms: insights from gene-targeted mice.

  2005cited by this paper
• Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.

  2005cited by this paper
• Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy

  2005cited by this paper
• Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.

  2005cited by this paper
• Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.

  2004cited by this paper
• The BCR-ABL story: bench to bedside and back.

  2004cited by this paper
• Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

  2004cited by this paper
• Balancing Akt with S6K

  2004cited by this paper
• Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.

  2003cited by this paper
• Overcoming resistance to imatinib by combining targeted agents.

  2003cited by this paper
• Critical role for Gab2 in transformation by BCR/ABL.

  2002cited by this paper
• Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase

  2001cited by this paper
• Synthesis and function of 3-phosphorylated inositol lipids.

  2001cited by this paper
• Ribosomal S6 Kinase 2 Inhibition by a Potent C-terminal Repressor Domain Is Relieved by Mitogen-activated Protein-Extracellular Signal-regulated Kinase Kinase-regulated Phosphorylation*

  2001cited by this paper
• Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit

  1998cited by this paper
• Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway

  1997cited by this paper
• Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3‐kinase inhibitors, wortmannin and LY294002.

  1996cited by this paper
• Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.

  1995cited by this paper

• Serum SERS Analysis Reveals Amino Acid- and Protein-Associated Vibrational Features for Subtype Identification in Acute Lymphoblastic Leukemia.

  2025cites this paper
• 1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation

  2023cites this paper
• Sterically enhanced control of enzyme-assisted DNA assembly

  2023cites this paper
• Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor

  2023cites this paper
• PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

  2023cites this paper
• Time-restricted feeding reduces monocyte production by controlling hematopoietic stem and progenitor cells in the bone marrow during obesity

  2022influential citation
• The TKI Era in Chronic Leukemias

  2021cites this paper
• The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells

  2021cites this paper
• Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function

  2021cites this paper
• Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses

  2021cites this paper
• Autophagy Does Not Contribute to TKI Response in a Imatinib-Resistant Chronic Myeloid Leukemia Cell Line

  2021cites this paper
• Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model

  2020cites this paper
• Cardio-renal Exosomes in Myocardial Infarction Serum Regulate Proangiogenic Paracrine Signaling in Adipose Mesenchymal Stem Cells

  2020cites this paper
• A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells

  2020cites this paper
• Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

  2020cites this paper
• A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

  2020cites this paper
• Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.

  2020cites this paper
• Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors.

  2020cites this paper
• From “Junk DNA” to Clinically Relevant Tools for Cancer Diagnosis, Staging, and Tailored Therapies: The Incredible Case of Non-Coding RNAs

  2019cites this paper
• PI3K‐PKB‐mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis

  2019cites this paper
• Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells

  2019cites this paper
• Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia

  2019cites this paper
• [The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].

  2019cites this paper
• Targeting mTOR in Acute Lymphoblastic Leukemia

  2019cites this paper
• The Network of Non-coding RNAs in Cancer Drug Resistance

  2018cites this paper
• 3 The PI 3 K / PKB Signaling Module in Normal and Malignant Hematopoiesis

  2018cites this paper
• Targeting the phosphatidylinositol 3‐kinase/Akt/mechanistic target of rapamycin signaling pathway in B‐lineage acute lymphoblastic leukemia: An update

  2018influential citation
• In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.

  2018cites this paper
• Taxodione induces apoptosis in BCR‐ABL‐positive cells through ROS generation

  2018cites this paper
• PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

  2017cites this paper
• Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.

  2017cites this paper
• Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

  2017cites this paper
• The Pathway in Human Disease.

  2017cites this paper
• mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL

  2017cites this paper
• Real-time quantitative analysis of metabolic flux in live cells using a hyperpolarized micromagnetic resonance spectrometer

  2017cites this paper
• Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

  2017cites this paper
• Inhibition of mTOR induces chemoresistance in B-cell acute lymphoblastic leukemia

  2017cites this paper
• Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development

  2017cites this paper
• Rare Hematological Malignancies in Children

  2017cites this paper
• MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.

  2017cites this paper
• Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

  2017cites this paper
• Constitutive Kit activity triggers B-cell acute lymphoblastic leukemia-like disease in mice.

  2017cites this paper
• Molecular processes involved in B cell acute lymphoblastic leukaemia

  2017cites this paper
• The PI3K Pathway in Human Disease.

  2017cites this paper
• PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

  2017cites this paper
• Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia

  2017cites this paper
• Genome-wide methylation profile following prenatal and postnatal dietary omega-3 fatty acid supplementation in pigs.

  2016cites this paper
• Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia

  2016cites this paper
• PTEN opposes negative selection and enables oncogenic transformation of pre-B cells

  2016cites this paper
• The Philadelphia chromosome in leukemogenesis

  2016cites this paper
• Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

  2016cites this paper
• Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.

  2016cites this paper
• Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia – preliminary report

  2016influential citation
• Targeting mTOR for the treatment of B cell malignancies.

  2016cites this paper
• Title Distinct GAB 2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL 1 Permalink

  2016cites this paper
• Rapamycin and rapalogs : partial mTORC 1 inhibitors Mechanism of action

  2016cites this paper
• Distinct GAB 2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL 1

  2016cites this paper
• Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma

  2016cites this paper
• Idelalisib induces G 1 arrest and apoptosis in chronic myeloid leukemia K 562 cells

  2016influential citation
• Forkheads in neuroblastoma & human longevity : From the womb to the tomb Santo

  2015cites this paper
• The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia

  2015cites this paper
• Forkheads in neuroblastoma & human longevity: From the womb to the tomb

  2015cites this paper
• Short-Term PTEN Inhibition Improves In Vitro Activation of Primordial Follicles, Preserves Follicular Viability, and Restores AMH Levels in Cryopreserved Ovarian Tissue From Cancer Patients

  2015cites this paper
• BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation

  2015cites this paper
• Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways

  2015cites this paper
• PI3K regulatory subunit p85alpha plays a tumor suppressive role in the transformation of mammary epithelial cells

  2015cites this paper
• TIGAR基因在恶性血液疾病中表达的机制研究进展

  2015cites this paper
• Aspekty kliniczne znaczenia kinazy mTOR w patogenezie ostrej białaczki limfoblastycznej u dzieci

  2015influential citation
• Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

  2015cites this paper
• 1 PI 3 K and Cancer : Lessons , Challenges and Opportunities

  2014cites this paper
• The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.

  2014cites this paper
• Somatic alterations as the basis for resistance to targeted therapies

  2014cites this paper
• Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis

  2014cites this paper
• Mammalian target of rapamycin inhibitor rapamycin enhances anti‐leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells

  2014cites this paper
• Cell Fate Reprogramming by Control of Intracellular Network Dynamics

  2014cites this paper
• Can we cure CML without transplantation

  2014cites this paper
• Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  2014cites this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cites this paper
• Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model

  2014cites this paper
• Role of different aberrant cell signalling pathways prevalent in acute lymphoblastic leukemia

  2014cites this paper
• Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

  2014cites this paper
• Targeting LKB1 signaling in cancer.

  2013cites this paper
• AKT is a therapeutic target in myeloproliferative neoplasms

  2013cites this paper
• Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells

  2013cites this paper
• Extreme Depletion of PIP3 Accompanies the Increased Life Span and Stress Tolerance of PI3K-null C. elegans Mutants

  2013influential citation
• Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia

  2013cites this paper
• mTOR pathway in colorectal cancer: an update

  2013cites this paper
• Molecular and Cellular Pathobiology FOXO 3 a Is a Major Target of Inactivation by PI 3 K / AKT Signaling in Aggressive Neuroblastoma

  2013cites this paper
• FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.

  2013cites this paper
• 1 FOXO 3 a Is A Major Target Of Inactivation By PI 3 K / AKT Signaling In Aggressive Neuroblastoma

  2013cites this paper
• Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

  2013cites this paper
• SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.

  2013cites this paper
• Novel and emerging drugs for acute lymphoblastic leukemia.

  2012cites this paper
• LYMPHOID NEOPLASIA SOX 4 enables oncogenic survival signals in acute lymphoblastic leukemia

  2012cites this paper
• [Treatment of acute lymphoblastic leukemia in childhood: state of things and outlook for the future].

  2012cites this paper
• Akt and mTOR in B Cell Activation and Differentiation

  2012cites this paper
• Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies

  2012cites this paper
• Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia

  2012cites this paper
• S6K1 determines the metabolic requirements for BCR-ABL survival

  2012cites this paper
• New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

  2012cites this paper